ROQUEFORT THERAPEUTICS PLC

Declaration of Voting Results & Voting Rights Announcements • Jun 26, 2025

National Storage Mechanism | Additional information

RNS Number : 6026O

Roquefort Therapeutics PLC

26 June 2025

26 June 2025

Roquefort Therapeutics plc

("Roquefort Therapeutics" or the "Company")

Results of AGM

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on developing first in class medicines in the high value and high growth immunology and oncology markets , is pleased to announce that at the Company's Annual General Meeting ("AGM") held earlier today, all resolutions proposed were duly passed.

The resolutions were put to shareholders via a poll, the results of which were as follows:

Resolution		Poll Results			Total Votes Withheld*
For	Against	Total Votes Cast
1	Shares	15,989,492	205,120	16,194,612	289,738
%	98.73%	1.27%
2	Shares	15,758,683	432,163	16,190,846	293,504
%	97.33%	2.67%
3	Shares	15,668,163	522,683	16,190,846	293,504
%	96.77%	3.23%
4	Shares	15,842,448	352,163	16,194,611	289,739
%	97.83%	2.17%
5	Shares	15,842,449	352,163	16,194,612	289,738
%	97.83%	2.17%
6	Shares	15,989,492	205,120	16,194,612	289,738
%	98.73%	1.27%
7	Shares	15,989,492	205,120	16,194,612	289,738
%	98.73%	1.27%
8	Shares	15,671,929	522,683	16,194,612	289,738
%	96.77%	3.23%
9	Shares	15,636,863	557,749	16,194,612	289,738
%	96.56%	3.44%

* Votes withheld are not counted in the calculation of the proportion of votes for and against a resolution.

The total number of ordinary shares in issue on 24 June 2025, the deadline for casting votes by proxy in advance of the AGM, was 157,444,030 shares.  10.3% of voting capital was instructed in respect of the resolutions put to the AGM.

Enquiries:

Roquefort Therapeutics plc	+44 (0)20 3918 8633
Stephen West (Chairman) / Dr Darrin Disley (Interim MD)
SP Angel Corporate Finance LLP (Broker) David Hignell / Vadim Alexandre / Devik Mehta	+44 (0) 20 3470 0470
Burson Buchanan (Public Relations) Ben Romney / Jamie Hooper	+44 (0)20 7466 5000
Peak IR (Investor Relations) Seb Wykeham	+33 (0)7 44 44 15 42

LEI: ‎254900P4SISIWOR9RH34

About Roquefort Therapeutics

Roquefort Therapeutics (LSE:ROQ) is developing first in class drugs in the immunology and oncology markets prior to securing a value accretive exit.

Roquefort Therapeutics' portfolio consists of five novel patent-protected pre-clinical anti-cancer and immunology assets. 

For further information on Roquefort Therapeutics, please   visit   www.roquefortplc.com  

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

RAGFLFSLREIRFIE